Cutia Therapeutics (stock short name: CUTIA-B) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 30 April 2026. The filing shows no changes to authorised capital or issued shares, but records reductions in its Pre-IPO equity incentives.

Authorised capital remained at 2.50 billion ordinary shares with a par value of USD0.00002, equivalent to total authorised capital of USD50,000.

Issued share capital was unchanged at 364.73 million shares, of which 1.36 million are held as treasury shares. The company confirmed that the public float exceeded the 25% requirement. No shares were issued, cancelled, or repurchased during the month.

Equity-incentive adjustments were the only notable movements: • Pre-IPO Share Option Program: 230,110 options were forfeited, trimming outstanding options to 18.95 million. Shares that could be issued upon full exercise stood at 18.41 million. • Post-IPO Equity Incentive Plan: no grants or exercises were recorded; 30.40 million shares remain available for future option grants. • Pre-IPO Share Award Program: 2.06 million share awards were forfeited, leaving 10.85 million shares available for issuance.

With no fresh issuances or treasury share transfers, CUTIA-B’s share structure stayed stable through April 2026, while the forfeitures modestly reduced potential dilution from legacy incentive schemes.